Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel. Formed in 1996 by merging Ciba-Geigy and Sandoz, it develops and sells prescription medicines.

Ciba-Geigy: Ciba-Geigy was a Swiss chemicals and pharmaceutical company that merged with Sandoz in 1996 to form Novartis. Its merger with Sandoz established Novartis.
Imatinib: Imatinib is a targeted cancer medicine that inhibits BCR-ABL and is used to treat chronic myeloid leukemia. Gleevec, Novartis’s imatinib brand, became a defining targeted therapy.
Gleevec: Gleevec is the brand name for imatinib, a targeted cancer drug developed by Novartis. Its success helped establish Novartis’s profile in precision oncology.
Roche: Roche is a Swiss multinational healthcare company specializing in pharmaceuticals and diagnostics. It is Novartis’s Basel-based peer and a frequent industry comparison.
Sandoz: Sandoz is a Swiss pharmaceutical company whose 1996 merger with Ciba-Geigy created Novartis. Its history supplied one half of Novartis’s founding merger.
Cosentyx: Cosentyx is a biologic medicine that blocks interleukin-17A and treats several inflammatory diseases. It exemplifies Novartis’s portfolio of immune-mediated disease treatments.
Novartis access-to-medicines programs: Novartis access-to-medicines programs are company initiatives intended to improve availability and affordability of treatments. These programs reflect the company’s response to barriers to medicine access.
Pfizer: Pfizer is an American multinational pharmaceutical company headquartered in New York City. Its scale and global drug portfolio provide a contrast with Novartis.
Ciba: Ciba was a Swiss chemicals and pharmaceutical company that became part of Ciba-Geigy through a 1970 merger. Its corporate lineage runs through Ciba-Geigy to Novartis.
Entresto: Entresto is a combination medicine containing sacubitril and valsartan, used to treat certain forms of heart failure. It is a major Novartis cardiovascular medicine.

Linked from 1 page

BayerCompared with: It competes with Bayer in selected therapeutic areas, including cardiovascular medicine.